Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Junction Carcinoma: early-phase trial registry
5 of 5 indexed Gastroesophageal Junction Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Gastroesophageal Junction Carcinoma: 5 US clinical trials tracked, 5 recruiting.
Gastroesophageal Junction Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is I-Mab Biopharma US Limited, running 2 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-junction-carcinoma
OPEN 5 | RECR 100% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Gastroesophageal Junction Carcinoma lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Junction Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Junction Carcinoma is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastroesophageal Junction Carcinoma research.
I-Mab Biopharma US Limited accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Junction Carcinoma enrolment sits around 180 participants.
Median target enrolment is 180 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Gastroesophageal Junction Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health
NCT05059444
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
NCT05563766
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07285044
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Junction Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Junction Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Junction Carcinoma page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Gastroesophageal Junction Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- I-Mab Biopharma US Limited sponsors the most Gastroesophageal Junction Carcinoma trials on record, review their full trial history before evaluating a specific study. See I-Mab Biopharma US Limited's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Junction Carcinoma condition card totals 5 registered trials; most-linked intervention TJ033721 (givastomig), durvalumab, chemotherapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.